CSL wins $230 million H1N1 vaccine order
Monday, 01 June, 2009
CSL's US subsidiary, CSL Biotherapies, has signed a $230 million (USD180 million) contract with the US Department of Health and Human Services (HHS) to provide Novel A (H1N1) influenza vaccine in bulk form.
CSL has also announced it will supply the Novel A (H1N1) vaccine to Australia.
The vaccine will be manufacturered at CSL's facility in Parkville, Victoria, and will support the HHS pre-pandemic influenza preparation efforts.
The new vccine will be tested in clinical trials funded by HHS.
CSL has declared that it will maintain its committment to supply seasonal influenza vaccines to Australia, the US and other markets.
Less penicillin needed to treat Strep A infection than we thought
It's never been known exactly how much penicillin prevents sore throats — the most...
Stress disrupts emotion control in mental illness
Acute stress may impair key brain functions involved in managing emotions — particularly in...
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
